May62021 Anavex Life Sciences to Announce Fiscal 2021 Second Quarter Financial Results and Business Outlook on Thursday, May 13, 2021 May 6, 2021
Apr122021 Anavex Life Sciences Reports the Results of Review by the Independent Data Safety Monitoring Board for its Phase 2/3 Trials of ANAVEX®2-73 in Patients with Rett Syndrome April 12, 2021
Mar42021 Anavex Life Sciences to Present at the H.C. Wainwright Global Life Sciences Conference March 4, 2021
Feb222021 Anavex Life Sciences Announces Participation at Upcoming Worldwide National Institutes of Health (NIH) Panel at Rare Disease Day® February 22, 2021
Feb182021 Anavex Life Sciences to Present at the 10th Annual SVB Leerink Global Healthcare Conference on February 25, 2021 February 18, 2021
Dec222020 Anavex Life Sciences to Announce Fiscal 2020 Year End Financial Results December 28th, 2020 December 22, 2020
Nov302020 Anavex Life Sciences Announces Notice of Allowance for U.S. Patent Application with Expanding Claims Covering ANAVEX®2-73 (blarcamesine) for the Treatment of Rett Syndrome and other Neurodevelopmental Disorders November 30, 2020
Nov252020 Anavex Life Sciences to Present at the Evercore ISI 3rd Annual HealthCONx Conference November 25, 2020
Aug62020 Anavex Life Sciences Reports Fiscal 2020 Third Quarter Financial Results And Provides Business Updates August 6, 2020
Aug52020 Anavex Life Sciences Receives TGA Special Access Scheme Approval for ANAVEX®2-73 (blarcamesine) for Alzheimer’s Disease Patients August 5, 2020
Aug42020 Anavex Life Sciences to Announce Fiscal 2020 Third Quarter Financial Results on Thursday, August 6th, 2020 August 4, 2020
